Mariam Menhem, MD
Endocrinology, Diabetes & Metabolism · New Orleans, LANPI 1194161901
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations.
Across 291 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$710
- Lilly USA, LLC$700
- Amgen$469
- Corcept Therapeutics$411
- Dexcom, Inc.$359
- AstraZeneca$340
- plus $2K from 36 others
What the payments were for
- Food & beverage$5,36699%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM CGM$239
How this compares
$5,411 in reported general payments places this provider in the 60th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 314 | $584,581 |
| JardianceEmpagliflozin | 348 | $455,734 |
| OzempicSemaglutide | 209 | $423,972 |
| TrulicityDulaglutide | 57 | $124,426 |
| TymlosAbaloparatide | 30 | $81,248 |
| Tresiba Flextouch U-100Insulin Degludec | 124 | $76,101 |
| FarxigaDapagliflozin Propanediol | 58 | $57,810 |
| JanuviaSitagliptin Phosphate | 36 | $42,412 |
| ProliaDenosumab | 15 | $25,562 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $25,036 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 131 | $20,482 |
| TradjentaLinagliptin | 13 | $18,498 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $16,390 |
| Repatha SureclickEvolocumab | 17 | $15,935 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 120 | $12,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $700 | $710,886386 claims |
| Boehringer IngelheimJardiance, Tradjenta | $209 | $474,232361 claims |
| Novo NordiskOzempic, Novolog | $710 | $430,914230 claims |
| Radius Health, Inc.Tymlos | $302 | $81,24830 claims |
| AstraZenecaFarxiga | $340 | $57,81058 claims |
| MerckJanuvia | $113 | $42,41236 claims |
| AmgenProlia | $469 | $25,56215 claims |
| AbbVieSynthroid | $305 | $3,54935 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $1,117174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in New Orleans
- Vivian FonsecaNew Orleans$658K
- Lawrence BlondeNew Orleans$142K
- Dragana LovreNew Orleans$14K
- Bryan GrissettNew Orleans$8K
- Melina Roman-GerardinoNew Orleans$7K
- Nyrene HaqueNew Orleans$5K
- Sarah SternliebNew Orleans$2K
- Suneeta GanjiNew Orleans$2K
- Timothy GilbertBaton Rouge$985K
- Abdul KhanHammond$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.